{"id":"conventional-antiarrhythmic-drug-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Proarrhythmia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Conventional antiarrhythmic drugs are classified into four main groups (Vaughan-Williams classification) that target different aspects of cardiac electrophysiology. Class I agents block sodium channels to slow conduction, Class II agents are beta-blockers that reduce automaticity, Class III agents block potassium channels to prolong repolarization, and Class IV agents block calcium channels to slow AV nodal conduction. These mechanisms collectively suppress ectopic activity and restore normal sinus rhythm in patients with various arrhythmias.","oneSentence":"Conventional antiarrhythmic drugs work by modulating cardiac electrical activity through various mechanisms including sodium channel blockade, beta-adrenergic antagonism, potassium channel inhibition, or calcium channel blockade to restore normal heart rhythm.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:37.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation management"},{"name":"Ventricular arrhythmias"},{"name":"Supraventricular tachycardia"}]},"trialDetails":[{"nctId":"NCT04239144","phase":"NA","title":"Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2018-11-09","conditions":"Chagas Cardiomyopathy, Ventricular Arrythmia","enrollment":45},{"nctId":"NCT07254455","phase":"NA","title":"CASTLE-HFpEF (Catheter Ablation for Atrial Fibrillation Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction)","status":"NOT_YET_RECRUITING","sponsor":"Tulane University","startDate":"2026-03","conditions":"Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction","enrollment":900},{"nctId":"NCT06322017","phase":"NA","title":"Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial Fibrillation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-04-09","conditions":"Atrial Fibrillation","enrollment":294},{"nctId":"NCT06418373","phase":"NA","title":"Development and Polit Study of Get Ready With my Heart Program","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2024-06-26","conditions":"Transition to Adult Care, Congenital Heart Disease","enrollment":30},{"nctId":"NCT05594368","phase":"PHASE1","title":"Dose Escalation for SBRT of Recurrent VT Ventricular Tachyarrhythmia - a Single Center, Phase II Clinical Trial","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2022-07-01","conditions":"Ventricular Tachycardia","enrollment":15},{"nctId":"NCT06660134","phase":"NA","title":"Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF","status":"COMPLETED","sponsor":"Shanghai Chest Hospital","startDate":"2021-08-01","conditions":"Type 2 Diabetes Mellitus (T2DM), Atrial Fibrillation (AF)","enrollment":174},{"nctId":"NCT02459574","phase":"NA","title":"Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-05-01","conditions":"Heart Failure, Recurrent Atrial Fibrillation","enrollment":321},{"nctId":"NCT02389218","phase":"PHASE4","title":"A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2015-03-03","conditions":"Atrial Fibrillation","enrollment":13},{"nctId":"NCT04702906","phase":"NA","title":"Trimetazidine As a Potential Adjuvant Therapy in Acute Aluminum Phosphide Poisoning-induced Cardiotoxicity","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2021-02","conditions":"Aluminum Phosphide Poisoning","enrollment":40},{"nctId":"NCT03857711","phase":"NA","title":"Randomized Clinical Trial PULVAB (Prophylactic Pulmonary Veins Ablation)","status":"UNKNOWN","sponsor":"National Research Center of Surgery, Russia","startDate":"2016-09-01","conditions":"Arrhythmias, Cardiac, Cardiovascular Diseases, Postoperative Atrial Fibrillation","enrollment":280},{"nctId":"NCT00392054","phase":"PHASE3","title":"First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2006-08","conditions":"Atrial Fibrillation","enrollment":127},{"nctId":"NCT03855826","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.","status":"UNKNOWN","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2019-01-15","conditions":"Ventricular Tachycardia, Ventricular Fibrillation","enrollment":756},{"nctId":"NCT00643188","phase":"PHASE4","title":"Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF","status":"COMPLETED","sponsor":"Biotronik SE & Co. KG","startDate":"2008-01","conditions":"Atrial Fibrillation, Heart Failure","enrollment":398},{"nctId":"NCT02294955","phase":"NA","title":"Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)","status":"UNKNOWN","sponsor":"Uppsala University Hospital","startDate":"2008-05","conditions":"Atrial Fibrillation, Quality of Life","enrollment":152},{"nctId":"NCT01108692","phase":"NA","title":"Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)","status":"COMPLETED","sponsor":"Biotronik France","startDate":"2010-07","conditions":"Atrial Fibrillation, Atrial Flutter, Atrial Tachycardia","enrollment":602},{"nctId":"NCT01709682","phase":"PHASE2","title":"A Comparison of the Drug Therapy Versus Re-Ablation","status":"COMPLETED","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2007-11","conditions":"Paroxysmal Atrial Fibrillation, Failed First Radiofrequency Ablation Procedure","enrollment":154}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Conventional Antiarrhythmic Drug Therapy","genericName":"Conventional Antiarrhythmic Drug Therapy","companyName":"Population Health Research Institute","companyId":"population-health-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Conventional antiarrhythmic drugs work by modulating cardiac electrical activity through various mechanisms including sodium channel blockade, beta-adrenergic antagonism, potassium channel inhibition, or calcium channel blockade to restore normal heart rhythm. Used for Atrial fibrillation management, Ventricular arrhythmias, Supraventricular tachycardia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}